IDH2 and acute myeloid leukemia: Enasidenib, formerly AG221, is an orally bioavailable small molecule inhibitor of mutant IDH2, which is FDA approved for the treatment of relapsed-refractory IDH2-mutated AML at a dose of 100 mg orally continuously daily.